Share

cover art for The PACER trial

Don't Just Read the Abstract

The PACER trial

Season 1, Ep. 1
•

In this, the first episode Drs Pip Nicolson and Rich Buka take a deep dive into the PACER trial: Platelet Transfusion before CVC Placement in Patients with Thrombocytopenia. After a quick round up of other trials that have sparked their interest, Pip and Rich discuss about the study aims and outcomes, before interviewing Dr Floor van Baarle, lead study author before discussing the clinical implications of the trial with Prof Simon Stanworth.


Follow Pip, Rich, and HaemSTAR on X/Twitter: @PipNicolson, @RichardBuka, and @HaemSTAR_UK


To claim CPD credits, please email haemstarnetwork@gmail.com.


Links



HaemSTAR is an independent UK-wide network of registrars in clinical haematology, interested in promoting and performing research in classical haematology. Our focus is on collaborative projects across haemostasis & thrombosis, transfusion, general haematology, and obstetric haematology.


This episode was sponsored by Sobi as a hands-off educational grant. Sobi had no editorial input whatsoever.


Produced by Joe Apperley. All rights reserved.

More episodes

View all episodes

  • 17. Efanesoctocog alfa for severe haemophilia A: expert perspective with Dr Susie Shapiro

    01:03:21||Season 1, Ep. 17
    On this episode, Pip interviews Dr Susie Shapiro, consultant haematologist in Oxford, UK, about the recent UK approval of efanesoctocog alfa, a very long half-life factor VIII product for severe haemophilia. To find out more about this treatment, listen to our first episode on the subject (Efanesoctocog alfa - a very long half life factor VIII) where we discuss the evidence.

  • 16. Efanesoctocog alfa - a very long half life factor VIII

    48:16||Season 1, Ep. 16
    On this episode, Rich and Pip discuss the very long half life factor VIII product efanesoctocog alfa (trade names Altuvoct and Altuviiio). They discuss the 2023 NEJM paper that has recently prompted its approval for use in the UK NHS. This is the first of two episodes on this subject.

  • 15. BSH Day 2

    23:55||Season 1, Ep. 15
    Pip and Rich discuss the happenings from day 2 of the British Society of Haematology Annual Scientific Meeting

  • 14. BSH Day 1

    31:40||Season 1, Ep. 14
    On this show, Pip and Rich discuss the first day of BSH, focusing on medical haematology.

  • Preview of BSH 2025: a focus on medical haematology

    52:43|
    In this episode, Rich and Pip review the programme for BSH 2025 and discuss the non-malignant haematology sessions not to miss. This is your go to guide for Glasgow 2025 beginning on 27th April.

  • PEERLESS - Management of Acute Intermediate-Risk PE

    01:05:31|
    On this episode, Pip and Rich discuss Jaber et al. Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial. PEERLESS was a trial that enrolled patients with intermediate-risk (sub-massive) PE and randomised them to either large-bore mechanical thrombectomy or catheter directed thrombolysis. The headline finding from PEERLESS is that mechanical thrombectomy is superior to catheter directed thrombolysis but as ever, if you read beyond the abstract, you will find that it is much more complex than that. The study used an interesting primary endpoint called "win ratio" and the show includes a detailed explanation and analysis of what this is, its benefits, and its drawbacks.

  • 11. AI powered ultrasound for DVT - an interview with CEO of ThinkSono, Fouad Al Noor

    01:02:44||Season 1, Ep. 11
    On this episode, Pip and Rich chat to Fouad Al Noor, CEO of ThinkSono. ThinkSono have developed an AI-powered handheld scanning tool for DVT that enables anyone to perform a diagnostic quality ultrasound scan for the diagnosis of DVT. The images are then reviewed by a radiologist, providing a rapid answer for most patients. The tool is entering use within the NHS and in this podcast, Pip and Rich discuss the story and the evidence behind ThinkSono as well as the challenges and opportunities that the tool provides.For more information, visit www.thinksono.com and to access the evidence, head to www.thinksono.com/research.Pip and Rich have no relevant conflicts of interest for this episode. The podcast was initially started thanks to a hands off grant from Sobi who have had no editorial input into the show.

  • 10. Iptacopan for PNH

    51:15||Season 1, Ep. 10
    In this episode, Rich and Pip discuss de Latour et al. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria. NEJM 2024. Iptacopan is a proximal complement inhibitor and the first oral treatment for paroxysmal nocturnal haemoglobinuria. The study randomised patients to either continuation of a C5 inhibitor or switch to ictacopan and found that a significant proportion of patients achieved hemoglobin levels of 120 g/L or higher without the need for transfusions. The treatment was generally well-tolerated, with a safety profile consistent with previous studies, suggesting that iptacopan is a viable alternative to existing therapies.Join us as we delve into the study's methodology, results, and implications for the future management of PNH.

  • 9. Plasma exchange free treatment of TTP: Author Discussion

    01:06:42||Season 1, Ep. 9
    In this episode, Pip and Rich discuss plasma exchange free treatment of thrombotic thrombocytopenic purpura with Dr Lucas Kuhne and Professor Paul Brinkoetter, authors of a recent study in Blood: Kühne et al. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange.The study is an observational, retrospective study reporting outcomes of patients with TTP who were treated without plasma exchange, which is currently considered the standard of care. The advent of a novel nanobody against vWF called caplacizumab, that targets and prevents catastrophic thrombosis that is seen in TTP, has allowed the study of this approach.
Copyright Richard Buka
Hosted with ❤️ by Acast